Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads

Executive Summary

Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq

You may also be interested in...



Menactra Returns To Normal Schedule; FluMist Seeks CDC Contract

FluMist CDC contract: MedImmune is negotiating a contract with the Centers for Disease Control & Prevention to supply its intranasal flu vaccine FluMist for the 2006-2007 season, VP & General Manager Mark Twyman says during a Oct. 25-26 meeting of CDC's Advisory Committee on Immunization Practices in Atlanta. The firm could supply the entire pediatric market by the 2008-2009 season, he says. Firm plans to produce 3 mil. doses of FluMist for the U.S. market for the current season and expects to have production, filling and distribution capacity for 20 mil. to 30 mil. doses for 2008-2009. MedImmune hopes to launch its refrigerator-stable version, CAIV-T (cold adapted influenza vaccine, trivalent), by next season. The firm hopes the non-freezer version will boost sluggish uptake...

Menactra Returns To Normal Schedule; FluMist Seeks CDC Contract

FluMist CDC contract: MedImmune is negotiating a contract with the Centers for Disease Control & Prevention to supply its intranasal flu vaccine FluMist for the 2006-2007 season, VP & General Manager Mark Twyman says during a Oct. 25-26 meeting of CDC's Advisory Committee on Immunization Practices in Atlanta. The firm could supply the entire pediatric market by the 2008-2009 season, he says. Firm plans to produce 3 mil. doses of FluMist for the U.S. market for the current season and expects to have production, filling and distribution capacity for 20 mil. to 30 mil. doses for 2008-2009. MedImmune hopes to launch its refrigerator-stable version, CAIV-T (cold adapted influenza vaccine, trivalent), by next season. The firm hopes the non-freezer version will boost sluggish uptake...

RotaTeq recommended

Merck's rotavirus vaccine RotaTeq was recommended for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices Feb. 21. The committee voted 12-0 with two abstentions for routine immunization of infants with three doses of the oral vaccine to be administered at two, four and six months of age. CDC analysis found that RotaTeq was not cost effective at the published price of $62 per dose, but could be cost effective at $42 per dose. RotaTeq was approved in early February (1"The Pink Sheet" Feb. 12, 2006, p. 25)...

Related Content

UsernamePublicRestriction

Register

PS046862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel